The most likely mechanism to deliver a malaria vaccine in African countries is through the
Expanded Program of Immunization (EPI). So far only SPf66, a multistage synthetic peptide …

Summary background Malaria control programmes need to protect young children, who
bear the brunt of malaria disease and death in Africa. The development of a vaccine is a …

The development of a malaria vaccine is a priority for improved and sustained malaria
control. Optimal use of a vaccine in Africa will only be achieved if it can be delivered through …

SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-
erythrocytic and asexual blood-stage proteins of Plasmodium falciparum. SPf66 was found …

Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting
results in different populations. We report a randomised double-blind trial of the SPf66 …

In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide
malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total …

The development of a safe, affordable and effective malaria vaccine to form part of control
schemes in malaria endemic countries is a priority for researchers and public health officials …

The demonstration of the i) acquired protective immunity in adults living in endemic areas, ii)
cure of malaria patients with passive transfer of specific immunoglobulins, and iii) protection …

As part of the first trial of the SPf66 malaria vaccine in Africa, three randomized double-blind
placebo-controlled studies of SPf66 have been conducted in a highly endemic area of …

Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66
vaccine is based on pre-erythrocytic and asexual blood-stage proteins of Plasmodium …